P3600Characteristics of 15mg od rivaroxaban patients from the RELOAD study

Abstract

Background: Only limited evidence exists regarding the characteristics of male and female patients treated with reduced dose rivaroxaban (15mg od) in nonvalvular atrial fibrillation (NVAF) from a real world setting in Germany. Purpose: The RELOAD study is a retrospective study, using a new user approach based on a representative sample of a German insurance claims database to assess the real world characteristics of male and female patients on reduced dose rivaroxaban in NVAF in Germany. Methods: The study analyses NVAF‐patients with an initial prescription of 15 mg od rivaroxaban between January 2012 and December 2015. Primary endpoints of this study will be the comparative risk of ischemic stroke (effectiveness) and intracranial haemorrhage (ICH, safety). This abstract analyses baseline characteristics of patients initiated on 15 mg rivaroxaban are stratified by gender descriptively. Results: Overall, 13,155 NVAF patients have been initiated on rivaroxaban (R). 3616 (27,5%) patients received the reduced dose of 15 mg od rivaroxaban, of which 60% were female. Female patients were older compared to male patients (mean age f:81,1; m: 76,7) and had a higher CHA2DS2‐VASC score on average (mean score f: 5,0; m: 3,7). While male patients show higher rates of prior myocardial infarction (f: 5,9%; m: 8,3%); chronic kidney disease (f: 30,8%; m: 32,4%), diabetes (f: 38,2%; m: 41,4%), coronary heart disease (f: 39,2%; m: 50,1%), female patients show more diagnoses of depression (f: 25,5%; m: 13,2%), anxiety disorder (f: 5,6%; m: 2,95) and dementia (f: 18,0%; m: 11,6%) as well as obesity (f: 21,3%; m: 19,0%). Conclusions: This study is the largest database study of its kind to date conducted in Germany. It contributes to the understanding of real‐world use of 15 mg od rivaroxaban in Germany. It shows that female patients are older than male 15 mg od initiators and have a higher CHA2DS2‐VASC score (Figure Presented).